Company Overview and News

 
MinRes, Brockman strike $300m mine deal

2018-07-27 businessnews.com.au
Mineral Resources and Brockman Mining have announced plans to jointly develop a major iron ore mine that will underpin construction of a new rail line and port facilities at Port Hedland.
BCK MALRY MALRF MIN

8
Fortescue puts pressure on Atlas Iron over port development

2018-06-27 australianmining.com.au
Atlas Iron has reinforced its position as a potential developer of facilities at Port Hedland, saying that it has no exclusive rights at the major Western Australian iron ore port in this regard.
AGO FSUMF BCK ATLGF AGODY MALRY FMG MALRF MIN FSUGY

4
Gina Rinehart makes $390m takeover bid Atlas Iron

2018-06-18 theage.com.au
Gina Rinehart has made a takeover bid for 100 per cent of Atlas Iron's shares, as the intriguing battle for control of the junior iron ore miner heats up.
AGO BCK ATLGF AGODY MALRY MALRF MIN

4
Gina Rinehart makes $390m takeover bid Atlas Iron

2018-06-18 smh.com.au
Gina Rinehart has made a takeover bid for 100 per cent of Atlas Iron's shares, as the intriguing battle for control of the junior iron ore miner heats up.
AGO BCK ATLGF AGODY MALRY MALRF MIN

4
Atlas Iron in trading halt, pending control proposal announcement

2018-06-18 theage.com.au
Iron ore miner Atlas Iron on Monday sought a trading halt of its shares pending an announcement regarding a "control transaction proposal" as the race for its ownership heats up.
AGO BCK ATLGF AGODY MALRY MALRF MIN

4
Atlas Iron in trading halt, pending control proposal announcement

2018-06-18 smh.com.au
Iron ore miner Atlas Iron on Monday sought a trading halt of its shares pending an announcement regarding a "control transaction proposal" as the race for its ownership heats up.
AGO BCK ATLGF AGODY MALRY MALRF MIN

8
Battle over Atlas Iron takes new turn

2018-06-08 theage.com.au
The intriguing corporate battle over the future of junior iron ore miner Atlas Iron has taken a new turn, with Atlas revealing on Friday afternoon that it could "explore discussions with other parties" about its future, after it reached agreement with Mineral Resources to change a recently developed Scheme Implementation Deed between the two companies.
AGO FSUMF BCK ATLGF AGODY MALRY FMG MALRF MIN FSUGY

8
Battle over Atlas Iron takes new turn

2018-06-08 smh.com.au
The intriguing corporate battle over the future of junior iron ore miner Atlas Iron has taken a new turn, with Atlas revealing on Friday afternoon that it could "explore discussions with other parties" about its future, after it reached agreement with Mineral Resources to change a recently developed Scheme Implementation Deed between the two companies.
AGO FSUMF BCK ATLGF AGODY MALRY FMG MALRF MIN FSUGY

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...